



February 9, 2022

To,  
The Corporate Relations Department  
The BSE Limited  
Department of Corporate Services  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400001.  
**Ref:- Scrip Code:- 500126**

To,  
The Listing Department  
The National Stock Exchange of India Limited  
Exchange Plaza, Plot No. C/1, G Block,  
Bandra Kurla Complex, Bandra (East),  
Mumbai – 400051  
**Ref:- Symbol:- PGHL**

Dear Sir / Madam,

**Sub:- Unaudited Financial Results for the quarter ended December 31, 2021**

We are pleased to inform you that at the meeting of the Board of Directors of the Company held today, the Unaudited Financial Results for the quarter ended December 31, 2021 were approved.

We are enclosing herewith the following:

- a. Unaudited Financial Results for the quarter ended December 31, 2021;
- b. Press Release; and
- c. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended December 31, 2021 furnished by Statutory Auditors of the Company

Kindly take the same on record and oblige.

Thanking you,  
Yours faithfully,

*For Procter & Gamble Health Limited*

*Milind Thatte*  
*Managing Director*

**Procter & Gamble Health Limited**

CIN: L99999MH1967PLC013726

Registered Office: Godrej One, 8<sup>th</sup> Floor,

Pirojshanagar, Eastern Express Highway, Vikhroli East,

Mumbai 400 079 | Tel: (91-22) 6866 9000

[www.pghealthindia.com](http://www.pghealthindia.com)

**PROCTER & GAMBLE HEALTH LIMITED**

Regd. Office: Godrej One, 8th Floor, Eastern Express Highway, Pirojshanagar, Vikhroli (East), Mumbai : 400 079.

CIN No. L99999MH1967PLC013726, email: investorgrievance.im@pg.com

**STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR AND QUARTER ENDED 31 DECEMBER 2021**

(₹ in lakhs)

Sr. No.	Particulars	(1)	(2)	(3)	(4)	(5)	(6)
		Three months ended 31st December 2021	Preceding Three months ended 30th September 2021	Corresponding Three months ended 31st December 2020	Half Year ended 31st December 2021	Half Year ended 31st December 2020	Year ended 30th June 2021
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1.	Revenue from Operations	27,790.0	27,280.0	24,022.0	55,070.0	50,419.0	100,873.0
2.	Other Income	470.0	304.0	572.0	774.0	1,244.0	1,810.0
3.	<b>Total income (1+2)</b>	<b>28,260.0</b>	<b>27,584.0</b>	<b>24,594.0</b>	<b>55,844.0</b>	<b>51,663.0</b>	<b>102,683.0</b>
4.	<b>Expenses</b>						
	a) Cost of materials consumed	9,163.0	9,299.0	4,667.0	18,462.0	13,972.0	28,912.0
	b) Purchases of stock-in-trade	524.0	651.0	426.0	1,175.0	942.0	2,116.0
	c) Changes in inventories of finished goods,work-in-progress and stock in trade	(653.0)	(1,697.0)	1,265.0	(2,350.0)	940.0	454.0
	d) Employee benefits expense	4,100.0	3,951.0	3,090.2	8,051.0	6,904.5	15,047.0
	e) Depreciation and amortisation expense	659.0	690.0	785.0	1,349.0	1,521.0	3,004.0
	f) Finance Costs	12.0	14.0	19.0	26.0	43.0	80.0
	g) Other expenses	8,472.0	7,269.0	5,698.8	15,741.0	10,975.5	29,742.0
	<b>Total expenses (4)</b>	<b>22,277.0</b>	<b>20,177.0</b>	<b>15,951.0</b>	<b>42,454.0</b>	<b>35,298.0</b>	<b>79,355.0</b>
5.	<b>Profit before exceptional items and tax (3-4)</b>	<b>5,983.0</b>	<b>7,407.0</b>	<b>8,643.0</b>	<b>13,390.0</b>	<b>16,365.0</b>	<b>23,328.0</b>
6.	Less: Exceptional items	-	-	-	-	-	-
7.	<b>Profit before tax (5-6)</b>	<b>5,983.0</b>	<b>7,407.0</b>	<b>8,643.0</b>	<b>13,390.0</b>	<b>16,365.0</b>	<b>23,328.0</b>
8.	<b>Tax expenses</b>						
	Current Tax	1,617.0	1,930.0	2,154.0	3,547.0	4,188.0	6,360.0
	Deferred Tax	10.0	(60.0)	(48.0)	(50.0)	(141.0)	(490.0)
	Tax for earlier years	(128.0)	-	(251)	(128.0)	(396)	(222.0)
9.	<b>Net Profit for the period/ year (7-8)</b>	<b>4,484.0</b>	<b>5,537.0</b>	<b>6,788.0</b>	<b>10,021.0</b>	<b>12,714.0</b>	<b>17,680.0</b>
10.	<b>Other Comprehensive Income</b>						
	Items that will not be reclassified to profit or loss						
	i. Re-measurement gains/(losses) on defined benefit plans	(336.0)	(22.0)	(963.0)	(358.0)	(990.0)	56.0
	ii. Income tax effect	84.0	6.0	242.0	90.0	249.0	(14.0)
	<b>Total Other Comprehensive Income, net of tax</b>	<b>(252.0)</b>	<b>(16.0)</b>	<b>(721.0)</b>	<b>(268.0)</b>	<b>(741.0)</b>	<b>42.0</b>
11.	<b>Total Comprehensive Income for the period/year (9+10)</b>	<b>4,232.0</b>	<b>5,521.0</b>	<b>6,067.0</b>	<b>9,753.0</b>	<b>11,973.0</b>	<b>17,722.0</b>
12.	Paid-up equity share capital (Face Value Rs 10/- each)	1,660.0	1,660.0	1,660.0	1,660.0	1,660.0	1,660.0
13.	Other equity excluding Revaluation reserve as per Balance sheet	-	-	-	-	-	68,711.0
14.	<b>Earnings per equity share (of Rs 10/- each)</b>						
	<b>*(not annualised)</b>						
	(a) Basic and Diluted (in Rs.)	* 27	* 33.4	* 40.9	* 60.4	* 76.6	* 106.5

**1. Statement of Assets and Liabilities**

(₹ in lakhs)

	As at December 31, 2021 [Unaudited]	As at June 30, 2021 [Audited]
<b>Non-current assets</b>		
(a) Property, plant and equipment	9,798	9,337
(b) Capital work-in-progress	3,622	3,915
(c) Investment property	277	295
(d) Right-of-use assets	507	747
(e) Intangible assets	7	12
(f) Financial assets		
(i) Loans	601	541
(ii) Other financial assets	853	818
(g) Deferred tax assets (net)	2,131	1,991
(h) Other non-current assets	597	609
(i) Non-current tax assets (Net)	8,191	7,637
<b>Total non-current assets</b>	<b>26,584</b>	25,902
<b>Current assets</b>		
(a) Inventories	14,292	11,837
(b) Financial assets		
(i) Trade receivables	7,551	5,943
(ii) Cash and cash equivalents	21,274	46,405
(iii) Bank balances other than (ii) above	483	486
(iv) Loans	154	145
(v) Other financial assets	991	598
(c) Other current assets	13,567	7,300
<b>Total current assets</b>	<b>58,312</b>	72,714
<b>TOTAL ASSETS</b>	<b>84,896</b>	98,616
<b><u>EQUITY AND LIABILITIES</u></b>		
<b>Equity</b>		
(a) Equity share capital	1,660	1,660
(b) Other equity	57,054	68,711
<b>Total Equity</b>	<b>58,714</b>	70,371
<b>Non-Current Liabilities</b>		
(a) Financial liabilities		
(i) Other financial liabilities	29	286
(c) Provisions	4,455	4,005
(b) Other non-current liabilities	58	57
<b>Total non-current liabilities</b>	<b>4,542</b>	4,348
<b>Current liabilities</b>		
(a) Financial liabilities		
Trade payables		
(i) total outstanding dues of micro enterprises and small enterprises	987	600
(ii) total outstanding dues of creditors other than micro enterprises and	11,985	12,276
(b) Other financial liabilities	7,525	9,586
(c) Other current liabilities	583	824
(d) Provisions	211	186
(e) Current tax liabilities (net)	349	425
<b>Total current liabilities</b>	<b>21,640</b>	23,897
<b>TOTAL EQUITY &amp; LIABILITIES</b>	<b>84,896</b>	98,616

## 2. Cash Flow Statement

	Half Year ended December 31, 2021 ₹ in lakhs	Year ended June 30, 2021 ₹ in lakhs
<b>A. Cash Flows from Operating Activities</b>		
Profit before tax	13 390	23 328
<b>Adjustments for:</b>		
Net unrealised foreign exchange loss	---	305
Allowance for doubtful receivables	( 71)	108
Bad debts	12	---
Inventory written off	9	48
GST input credit provided/ written off	269	354
Depreciation of property, plant and equipment	1 349	3 004
Income from letting of office premises	( 108)	( 209)
Provision for employee benefits	256	537
Loss on sale of property, plant and equipment	50	42
Share-based payment to employees	169	193
Finance Cost	26	80
Interest income	( 550)	( 1 506)
<b>Operating profit before working capital changes</b>	<b>14 801</b>	<b>26 284</b>
Working capital adjustments:		
(Increase)/Decrease in inventories	( 2 446)	1 526
(Increase)/Decrease in trade receivables	( 1 525)	3 470
(Increase)/Decrease in financial and other Assets	( 7 023)	( 684)
Increase in trade payables	96	181
(Decrease)/ Increase in other liabilities and provisions	( 2 729)	762
<b>Cash generated from operations</b>	<b>1 173</b>	<b>31 538</b>
Income taxes paid (net)	( 4 049)	( 6 812)
<b>Net cash generated from operating activities (A)</b>	<b>( 2 876)</b>	<b>24 726</b>
<b>B. Cash Flows from Investing Activities</b>		
Purchase and construction of property, plant and equipment	( 1 099)	( 5 258)
Proceeds from sale of asset	13	121
Income from letting of office premises	108	209
Interest received	542	1 708
Security deposit placed against commitments	( 7)	( 7)
<b>Net cash (used in)/ generated from investing activities (B)</b>	<b>( 443)</b>	<b>( 3 227)</b>
<b>C. Cash flow from financing activities</b>		
Dividend paid	( 21 579)	( 38 178)
Payment of lease liability	( 232)	( 485)
<b>Net cash flow used in financing activities (C)</b>	<b>( 21 811)</b>	<b>( 38 663)</b>
<b>Net (decrease)/ increase in cash and cash equivalents (A+B+C)</b>	<b>( 25 130)</b>	<b>( 17 164)</b>
Cash and cash equivalents at the beginning of the period/ year	46 405	63 569
<b>Cash and cash equivalents at the end of the year/ period</b>	<b>21 274</b>	<b>46 405</b>
<b>Components of Cash and Cash equivalents:</b>		
Cheque in hand	---	457
Balance with Banks		
In Current accounts	3 224	4 638
In Term deposits ( less than 3 months maturity)	18 050	41 310
	<b>21 274</b>	<b>46 405</b>

MILIND  
VASANT  
THATTE

Digitally signed  
by MILIND  
VASANT THATTE  
Date: 2022.02.09  
12:39:15 +05'30'

## PROCTER & GAMBLE HEALTH LIMITED

Regd. Office: Godrej One, 8th Floor, Eastern Express Highway, Pirojshanagar, Vikhroli (East), Mumbai : 400 079.

CIN No. L99999MH1967PLC013726, email: [investorgrievance.im@pg.com](mailto:investorgrievance.im@pg.com)

### Notes:

3. The above financial results for the quarter and half year ended December 31, 2021 have been reviewed by the Audit Committee, and approved by the Board of Directors of the Company at their Meeting held on February 9, 2022 and have been subject to a limited review by the Statutory Auditors of the Company.
4. Results for all above period have been prepared in accordance with Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standard) Rules, 2015, as amended.
5. The Company operates under only one segment i.e. Pharmaceuticals. Accordingly, no separate segment information has been provided.
6. Previous period figures have been regrouped/ reclassified wherever necessary.

For and on behalf of the Board of Directors of  
Procter & Gamble Health Limited.

MILIND  
VASANT  
THATTE

Digitally signed by  
MILIND VASANT THATTE  
Date: 2022.02.09  
12:38:24 +05'30'

Milind Thatte  
Managing Director

Place : Mumbai

Date : 9 February 2022

Please visit us at our website [www.pghealthindia.com](http://www.pghealthindia.com)



## Procter & Gamble Health Limited Announces Half Yearly results

*Sales up by 15% for quarter ended December 31, 2021*

**Mumbai, Feb 10, 2022:** Procter & Gamble Health Limited announced today its financial results for the quarter ended December 31, 2021. The company has recorded a total sale of ₹ 273 crores for the quarter ended December 31, 2021, vs ₹ 238 Crores a year ago, up by 15%. The Profit After Tax (PAT) was ₹ 44.8 crores vs ₹ 67.9 crores a year ago due to higher investments in marketing initiative to support growth in current year and help of one time reversals in the base period. Sales for the six-month period ending December 31, 2021, were ₹ 541 crores, vs ₹ 496 Crores a year ago, up by 9%. Profit After Tax for same period was ₹ 100.2 Crore vs ₹127.1 Crore a year ago.

**Milind Thatte, Managing Director, Procter & Gamble Health Limited said,** *“The Company has delivered sales of ₹ 273 Crores in a challenging quarter growing by 15% over year ago on the back of continued demand for our quality and affordable vitamins, minerals, and medicinal products. The pandemic has made consumers overall more cognizant of their health and wellness needs, with a growing demand for trusted brands for themselves and their families as they live in the new normal. Our teams continued to step up on category and brand building efforts through innovative scientific forums, consumer awareness and pharmacy education initiatives.*

*The Company, in association with FOGSI (The Federation of Obstetric and Gynaecological Societies of India), achieved a new GUINNESS WORLD RECORD™ title, for its efforts on creating awareness on Iron Deficiency Anemia. The Company launched ‘P&G Health Academy’ a new scientific education platform for Doctors, and also initiated a new sustainability initiative for Pharmacies under its flagship CSR program ‘SEHAT’ (meaning Health), among various other initiatives. We are delighted to share that SEHAT recently bagged the prestigious Gold in the ‘Best Public Health Initiative’ category at the India Health and Wellness Awards supported by Niti Aayog. With continued focus on health and safety, the Company also introduced a host of initiatives towards supporting wellness needs of our employees. The Company has made significant progress in its gender diversity efforts recording a 4x increase in the number of women in the sales hierarchy over the last 12 months,” he added.*

### About Procter & Gamble Health Limited:

Procter & Gamble Health Limited is one of India’s largest VMS companies manufacturing and marketing over-the-counter vitamins, minerals, and supplements products for a healthy lifestyle and improved quality of life, including Neurobion, Livogen, SevenSeas, Evion, Polybion and Nasivion. Please visit [www.pghealthindia.com](http://www.pghealthindia.com) for the latest news and information about Procter & Gamble Health Limited and its brands.

### About Procter & Gamble:

P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Ambi Pur®, Ariel®, Gillette®, Head & Shoulders®, Olay®, Oral-B®, Pampers®, Pantene®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide.

### CONTACTS

#### Media Contacts - Procter & Gamble Health Limited:

- Ruchita Mehra | [mehra.r@pg.com](mailto:mehra.r@pg.com)
- Paromita Kundu | [kundu.p.1@pg.com](mailto:kundu.p.1@pg.com)

#### Investor Relations Contact:

- Flavia Machado | [machado.f.1@pg.com](mailto:machado.f.1@pg.com)

### Registered Office :

**Procter & Gamble Health Limited**  
 CIN: L99999MH1967PLC013726  
 Godrej One, 8<sup>th</sup> Floor, Pirojshanagar,  
 Eastern Express Highway, Vikhroli East,  
 Mumbai 400 079 | Tel: (91-22) 6866 9000

### Site Address:

**Procter & Gamble Health Limited**  
 CIN: L99999MH1967PLC013726  
 Usgaon, Ponda Taluka,  
 Goa 403 407 | Tel: (91-832) 2347105  
[www.pghealthindia.com](http://www.pghealthindia.com)

# HARIBHAKTI & CO. LLP

Chartered Accountants

**Independent Auditor’s Review Report on quarterly and year to date Unaudited Financial Results of Procter & Gamble Health Limited pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.**

To the Board of Directors

Procter & Gamble Health Limited

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **Procter & Gamble Health Limited** (“the Company”) for the quarter ended December 31, 2021 and for the period from July 01, 2021 to December 31, 2021 (“the Statement”), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company’s Management and approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting” as prescribed under Section 133 of Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of the company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



# HARIBHAKTI & CO. LLP

Chartered Accountants

4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Haribhakti & Co. LLP

Chartered Accountants

ICAI Firm Registration No.103523W/W100048



Hemant J. Bhatt

Partner

Membership No.: 036834

UDIN: 22036834AAYXC12070

Place: Mumbai

Date: February 09, 2022